Aster DM Healthcare Ltd

- Aster DM Healthcare currently has a strong cash position with net cash of INR 1,014 crores as of December 31, 2024. - The company generates very good cash flow from operations (80-85% of pre-IndAS EBITDA) and free cash flow. - For the planned 1,700 beds expansion over the next three years, they estimate a funding requirement of approximately INR 1,100 crores. - Management expects to fund expansion through internal cash flow without needing additional borrowings. - Existing lines of credit are sufficient; the company is not looking to raise new debt. - They remain open to inorganic expansion opportunities but have no immediate plans for equity fundraising, prioritizing shareholder returns via dividend now. - Overall, the focus is on organic growth funded by internal accruals with no current plans for new debt or equity fundraising.

- Capital expenditure totaled INR 238 crores for 9M FY25, with about 65% directed towards capacity expansion. - Over the next three years, the company plans to add nearly 1,700 beds, mainly via brownfield expansions to maintain margins. - Specific projects include: - Women and children block with 150 beds expected operational in H1 FY26. - Kasargod hospital with 260 beds (north Kerala) also expected in H1 FY26. - Small brownfield expansion in Ongole with 75 beds. - Tower 4 of 100 beds at Aster Medcity commissioned recently. - Pipeline of approximately 1,700 beds to expand total capacity to over 6,800 beds by FY27. - Investment in a 26-megawatt solar power plant in Kerala, expected to partially operate by Q1 FY26, with annual savings of INR 15-16 crores. - Expansion funded primarily through internal accruals with net cash of INR 1,000+ crores; no additional borrowing planned for expansions.

- Hospital & Clinics segment grew over 17% in revenue; mature hospitals showing strong margins. - Karnataka & Maharashtra cluster revenue grew 33% YoY. - Kerala cluster revenue grew 8% YoY with occupancy at 74%. - Andhra & Telangana cluster revenue grew 16% YoY. - Outpatient visits up 11%, inpatient visits up 10% YoY in 9M FY25. - Lab business grew 14% YoY in 9M FY25; external business growing 27% YoY. - Expect non-Aster lab business growth of 35-40% in coming year. - Plans to add ~1,700 beds by FY27, mostly via brownfield expansions. - Hospital and clinic segment margins expected to reach 24% by FY27. - Consolidated margins aimed to be above 21% by FY27. - Labs expected to exceed 20% margin in coming years. - Wholesale pharmacy business expected to shrink due to slower growth.

- Consolidated margin expected to increase from ~19.5% (9M FY25) to above 21% by FY27. - Hospital and clinic segment margins targeted to rise from 22.3% (9M FY25) to upwards of 24% by FY27. - Labs business projected to exceed 20% margins due to its high-margin nature. - Growth in non-Aster business within labs expected at 35-40% in the coming year, supporting margin expansion. - Operating EBITDA margins have grown by ~300 bps YoY to 19.5% (9M FY25), expected to further improve with ongoing efficiencies. - ROCE for Hospital & Clinics increased to 25.8%; matured hospitals at 35.7%, indicating efficient capital utilization backing profit growth. - Revenue growth driven by 15% YoY increase and operational improvements expected to sustain upward earnings momentum. - Cash flows and internal accruals adequate to support expansion without added debt, supporting future EPS growth potential.

The transcript does not explicitly mention the current or expected order book or pending orders for Aster DM Healthcare. However, the following related points provide insight into their growth and expansion plans: - The company plans to add approximately 1,700 beds by FY27, increasing total capacity from 5,128 beds (as of Dec 31, 2024) to over 6,800 beds. - Major brownfield projects are underway at key hospitals: Aster Medcity (~950 beds), Aster CMI (~850 beds), and Aster Whitefield (~500 beds). - Expansion pipeline is progressing steadily with capacity enhancements. - The company is focused on organic and inorganic growth, including a merger under regulatory approval. - Lab business is performing strongly with positive EBITDA and expansion in locations. - Pharmacy business sees strategic changes amid muted growth. No specific order book values or pending order amounts are disclosed in the call transcript.